MedPath

TRough vs AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in allogeneic stem cell recipients

Recruiting
Conditions
allogeneic stem cell transplantationcyclosporineTDMAdverse drug reactions
Registration Number
NL-OMON27177
Lead Sponsor
VU University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Age 18-65 inclusive

- AML, MDS, ALL, MM, CML, CLL, NHL, HL, or a myeloproliferative disease (MPD)

Exclusion Criteria

- Renal dysfunction (serum creatinine > 150 umol/L or clearance < 50 ml/min)

- Patients with active, uncontrolled infection

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- Grade acute kidney injury<br /><br>- Grade nausea <br /><br>- Grade in tremor <br /><br>
Secondary Outcome Measures
NameTimeMethod
Adverse drug reactions <br /><br>- Headache <br /><br>- Hypertension<br /><br><br /><br>Clinical chemical parameters:<br /><br>- Glucose<br /><br>- Potassium<br /><br>- Magnesium<br /><br>- Total cholesterol<br /><br>- High-density lipoproteins<br /><br>- Liver function<br /><br><br /><br>Other parameters:<br /><br>- Grade GVHD<br /><br>- Minimal residual disease on day 28; 56; 84; 112; 140 ; 168<br /><br>- Engraftment<br /><br>- Quality of life (QoL) will be assessed by means of the validated questionnaires.<br />
© Copyright 2025. All Rights Reserved by MedPath